[Skip to Content]
[Skip to Content Landing]
November 1990

Treatment of Severe Reactive Hypoglycemia With a Somatostatin Analogue (SMS 201-995)

Author Affiliations

From the Department of Endocrinology, III, Medizinische Klinik, University of Mainz (West Germany).

Arch Intern Med. 1990;150(11):2401-2402. doi:10.1001/archinte.1990.00390220133029

• Reactive (or postprandial) hypoglycemia can sometimes represent a severe disorder refractory to conventional therapeutic measures. We present in this first individual trial, to our knowledge, that the administration of a somatostatin analogue (SMS 201 -995) may alleviate the severity of complaints and does not appear to be diabetogenic. The effects of the somatostatin analogue were documented in a 5-hour oral glucose tolerance test, where not only the glucose-induced and C-peptide rise was clearly attenuated, but also the blood glucose concentration did not fall low enough to induce hypoglycemic symptoms.

(Arch Intern Med. 1990;150:2401-2402)